Stock 600535 TASLY PHARMACEUTICAL GROUP CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tasly Pharmaceutical Group Co., Ltd

Equities

600535

CNE000001C81

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 26/06/2024 BST 		5-day change 1st Jan Change
12.56 CNY -2.71% Intraday chart for Tasly Pharmaceutical Group Co., Ltd -5.14% -26.20%
06-20 Tasly Pharmaceutical Group's Allergy Tablet Passes Drug Quality, Efficacy Evaluation MT
04-25 Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 23,252 22,302 23,778 15,988 25,427 18,764 - -
Enterprise Value (EV) 1 29,451 23,121 23,086 14,968 23,635 16,058 15,243 14,335
P/E ratio 23.4 x 19.7 x 10.1 x -63.3 x 23.6 x 15.3 x 13.1 x 12.4 x
Yield 2.14% 2.23% 2.08% 3.07% 1.94% 2.78% 2.92% 3.29%
Capitalization / Revenue 1.22 x 1.64 x 2.99 x 1.86 x 2.93 x 2.07 x 1.89 x 1.84 x
EV / Revenue 1.55 x 1.7 x 2.9 x 1.74 x 2.72 x 1.77 x 1.53 x 1.4 x
EV / EBITDA 16.7 x 11.2 x 7.32 x 50.8 x 14.2 x 7.63 x 6.53 x 6.11 x
EV / FCF - 16.6 x - - - 13.4 x 15 x 12.7 x
FCF Yield - 6.01% - - - 7.46% 6.67% 7.9%
Price to Book 2.1 x 1.87 x 1.83 x 1.3 x 2.06 x 1.42 x 1.32 x 1.23 x
Nbr of stocks (in thousands) 1,507,920 1,507,920 1,500,163 1,485,873 1,493,950 1,493,950 - -
Reference price 2 15.42 14.79 15.85 10.76 17.02 12.56 12.56 12.56
Announcement Date 25/04/20 23/04/21 30/03/22 27/03/23 15/04/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 18,998 13,576 7,952 8,593 8,674 9,080 9,951 10,203
EBITDA 1 1,762 2,062 3,153 294.6 1,663 2,104 2,334 2,347
EBIT 1 1,338 1,472 2,733 -153 1,228 1,413 1,616 1,704
Operating Margin 7.04% 10.85% 34.37% -1.78% 14.16% 15.56% 16.24% 16.7%
Earnings before Tax (EBT) 1 1,331 1,457 2,724 -160.5 1,221 1,490 1,704 1,814
Net income 1 1,001 1,126 2,359 -256.5 1,071 1,247 1,441 1,516
Net margin 5.27% 8.29% 29.66% -2.99% 12.35% 13.73% 14.48% 14.86%
EPS 2 0.6600 0.7500 1.570 -0.1700 0.7200 0.8207 0.9556 1.013
Free Cash Flow 1 - 1,389 - - - 1,199 1,016 1,132
FCF margin - 10.23% - - - 13.2% 10.21% 11.09%
FCF Conversion (EBITDA) - 67.33% - - - 56.98% 43.55% 48.24%
FCF Conversion (Net income) - 123.34% - - - 96.13% 70.51% 74.66%
Dividend per Share 2 0.3300 0.3300 0.3300 0.3300 0.3300 0.3488 0.3666 0.4134
Announcement Date 25/04/20 23/04/21 30/03/22 27/03/23 15/04/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - - - - 2,103 2,049 2,541 2,471 2,896 - -
EBITDA - - - - - - - - - - - - - - -
EBIT - - - - - - - - - - - - - - -
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - - - -
Net income - - - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - - - -
EPS 2 0.5800 -0.3719 0.1000 0.0500 0.0500 0.1774 0.2900 0.2200 0.0300 0.1976 0.2200 0.2300 0.3300 0.3000 0.2800
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 30/03/22 25/04/22 19/08/22 25/10/22 27/03/23 24/04/23 25/08/23 27/10/23 15/04/24 25/04/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 6,199 818 - - - - - -
Net Cash position 1 - - 692 1,020 1,792 2,706 3,521 4,429
Leverage (Debt/EBITDA) 3.518 x 0.3968 x - - - - - -
Free Cash Flow 1 - 1,389 - - - 1,199 1,016 1,132
ROE (net income / shareholders' equity) 9.28% 9.76% 18.4% -2.04% 8.75% 9.64% 10.3% 10.1%
ROA (Net income/ Total Assets) 4.07% 5.56% 14.3% - 7.12% 6.65% 7.39% 7.47%
Assets 1 24,593 20,253 16,518 - 15,049 18,751 19,511 20,307
Book Value Per Share 2 7.360 7.910 8.660 8.270 8.250 8.840 9.520 10.20
Cash Flow per Share 2 1.110 1.180 1.870 1.520 1.720 1.100 1.090 1.440
Capex 1 729 403 503 402 668 506 416 413
Capex / Sales 3.84% 2.96% 6.32% 4.68% 7.7% 5.57% 4.18% 4.04%
Announcement Date 25/04/20 23/04/21 30/03/22 27/03/23 15/04/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Tasly Pharmaceutical Group Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
12.56 CNY
Average target price
16.17 CNY
Spread / Average Target
+28.76%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Alternative Medicine

1st Jan change Capi.
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
-26.20% 2.65B
DONG-E-E-JIAO CO.,LTD. Stock Dong-E-E-Jiao Co.,Ltd.
+28.10% 5.68B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-33.42% 3.61B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
-3.33% 3.11B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
-9.99% 2.33B
HENAN LINGRUI PHARMACEUTICAL CO., LTD. Stock Henan Lingrui Pharmaceutical Co., Ltd.
+40.09% 1.89B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD Stock Zhejiang Jolly Pharmaceutical Co.,LTD
+40.90% 1.49B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
-12.94% 1.46B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK Stock PT Industri Jamu dan Farmasi Sido Muncul Tbk
+46.67% 1.37B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. Stock GuangYuYuan Chinese Herbal Medicine Co., Ltd.
-30.31% 1.31B
Alternative Medicine
  1. Stock Market
  2. Equities
  3. 600535 Stock
  4. Financials Tasly Pharmaceutical Group Co., Ltd